Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH
December 2, 2016
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim